Pablo Corral on Enlicitide: The Phase 3 CORALreef HeFH Trial Brings a Major Step Forward
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on LinkedIn:
”Breaking from AHA25
The phase 3 CORALreef HeFH trial brings a major step forward: the first oral PCSK9 inhibitor, enlicitide, cuts LDL-C by ≈60% vs placebo in adults with heterozygous familial hypercholesterolemia already on maximally tolerated statins.
- LDL-C ↓58% at 24 weeks and sustained −55% at 52 weeks
- ApoB ↓48%, non-HDL-C ↓52%, Lp(a) ↓25%
- >70% reached LDL < 70 mg/dL, with excellent tolerability
- No excess in adverse events vs placebo
Enlicitide (oral PCSK9 inhibitor, 20 mg QD) shows efficacy comparable to injectable antibodies — potentially transforming lipid management for HeFH and beyond. doi:10.1001/jama.2025.20620”
Read the full article here.
Article: Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia
Authors: Christie M. Ballantyne, Laura Gellis, Jean-Claude Tardif, Puja Banka, Ann Marie Navar, Emil Andreas Asprusten, Russell Scott, Erik S. G. Stroes, Samar Froman, Geraldine Mendizabal, Fan Wang, Alberico L. Catapano
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 8, 2026, 12:48Denis Oduor: Beyond the Donation Chair and Into a Legacy of Hope
-
Sep 8, 2026, 12:24Alejandro González Veliz: Can a Stent Cause a Heart Attack?
-
Sep 8, 2026, 11:15Andreas Tridimas: Atherosclerosis Is Greyer Than We Admit
-
Sep 8, 2026, 10:59Eman M. Elsabbagh: Pediatric Nonmalignant HCT Enters the Era of Precision Conditioning and Gene Therapy
-
Sep 8, 2026, 10:50Dena Winchester: Sponsored Genetic Testing Programs Improve Access for Children With Hemophilia A
-
Sep 8, 2026, 10:49Alessandra Bosch: Von Willebrand Disease and Rare Bleeding Disorders, Collaborative Insights and Patient Empowerment
-
Sep 8, 2026, 09:42Vineet Sankhla: Rethinking Potent P2Y12 Inhibition in AF Patients Undergoing PCI
-
Sep 8, 2026, 09:23Mehdi Mirsaeidi: Platelets and Thromboinflammation in COPD
-
Sep 8, 2026, 09:03Michel Cabrera Ortega: LAAC vs OAC – Which Risk Are We Trading?